A Greenburg Traurig team represented Intec Pharma Ltd. in a public offering that raised $57.5 million that the company intends to use to fund further clinical trials of a product that could improve the treatment of symptoms of advanced Parkinson's disease.

The platform technology on which the product is based is also part of a proposed medical marijuana drug that is in clinical trials in Israel.

Intec Pharma is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, which is meant to increase the amount of time a medication is available for absorption in the gastrointestinal tract. The company intends to use money from the recent offering to fund Phase III clinical trials for Accordion Pill Carbidopa/Levodopa for Parkinson's disease symptoms, as well as for working capital and general corporate purposes.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Go To Lexis →

Not a Lexis Subscriber?
Subscribe Now

Go To Bloomberg Law →

Not a Bloomberg Law Subscriber?
Subscribe Now

NOT FOR REPRINT